TABLE 5.
Susceptibilities of seven patient-derived viral isolates to representative drugs assayed using R5-MaRBLE cells
| Strain or isolate (subtype) | Tropismb | RT mutation(s) | Protease mutation(s) | IC50 (nM) ± SD (change, n-fold) of:
|
|||
|---|---|---|---|---|---|---|---|
| Zidovudine | Lamivudine | Efavirenz | Lopinavir | ||||
| JRCSF (B) | R5 | None | L63P | 1.4 ± 0.6 (1) | 13.6 ± 4.6 (1) | 0.9 ± 0.1 (1) | 19.3 ± 8.4 (1) |
| 1 (B) | R5 | None | L63P/T, A71A/V, V77I | 1.2 (0.7) | 4.2 (0.3) | 1.5 (1.8) | 6.8 (0.5) |
| 2 (B) | X4, R5 | M41L, D67N, K70R, K101Q, M184V, L210L/W, T215F, K219Q | L10I, L33F, M46I, F53L, I54V, L63P, A71V, G73S/T, V77I, V82F, L90M | 56.1 (32.9) | >5,000 (>380.7) | 1.1 (1.3) | >1,000 (>76.5) |
| 3 (F) | X4, R5 | M41L, E44E/D, D67N, K101K/E, V118I, L210W, T215Y | K20T, D30N, M36I, M46M/L, L63P, A71V, N88D | 195.1 (114.5) | 34.5 (2.6) | 0.1 (0.2) | NDc (ND) |
| 4 (B) | X4, R5 | M41L, E44A, D67N, V118I, L210W, T215Y | L10V, K20T, D30N, M36I, I54V, L63T, A71V, V77V/I, N88D, L90M | 326.5 (191.7) | 13.5 (1.0) | 0.2 (0.2) | 123.4 (9.4) |
| 5 (B) | X4, R5 | M41L, E44D, D67N, V118I, M184V, L210W, T215Y | L10V, K20R, V32I, M36I, M46L, F53F/L, I54V, L63P, A71V, V82A, L90M | 177.4 (104.1) | >5,000 (>380.7) | 0.5 (0.6) | 986.8 (75.5) |
| 6 (F) | R5 | M41L, E44D, D67N, V118I, L210W, T215Y | L10I, K20T, M36I, M46I, F53L, L63L/I/T/P, A71V, I84V, L90M | 381.7 (224.0) | 88.0 (6.7) | 0.3 (0.4) | 190.6 (14.6) |
| 7Ra (B) | X4 | K103N | L63C, V77I | 2.1 (1.5) | 22.3 (1.6) | 60.2 (66.8) | 7.6 (0.4) |
a
Recombinant HXB2 with patient-derived protease and RT sequences.
b
The tropism of each virus was determined by using X4-GHOST and R5-GHOST cells.
c
ND, not determined.